SLU-PP-332
SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors ERR-alpha, beta, and gamma, described as an 'exercise mimetic' because it switches on the acute aerobic-exercise gene program in mouse muscle. It is entirely preclinical: every published in vivo study is in mice, there is no human dosing, and the developers themselves report the compound lacks oral bioavailability.
Reference only, for adults following preclinical exercise-mimetic pharmacology. There is no human safety profile, no regulatory approval anywhere, and no established human dose — nothing in the literature supports self-administration.
The estrogen-related receptors ERR-alpha, ERR-beta, and ERR-gamma are orphan nuclear receptors — structurally related to the estrogen receptor but not activated by estrogen — that govern transcription of genes for mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle. They are among the transcriptional machinery skeletal muscle uses to adapt to aerobic training, which makes them an obvious target for a pharmacological exercise mimetic. SLU-PP-332, developed in Thomas Burris's laboratory, is a synthetic pan-agonist across all three receptors with the greatest potency at ERR-alpha.
In the 2023 ACS Chemical Biology paper that introduced it, the compound enhanced mitochondrial function and cellular respiration in cultured skeletal muscle cells, induced an ERR-alpha-specific acute aerobic exercise gene program, increased type IIa oxidative muscle fibers, and improved running endurance in mice, with the effect on exercise capacity shown to depend on ERR-alpha. A 2024 follow-up in the Journal of Pharmacology and Experimental Therapeutics extended this to diet-induced obese and ob/ob mice, where administration increased whole-body energy expenditure and fatty acid oxidation, reduced fat-mass accumulation, and improved glucose tolerance and insulin sensitivity. Related work has reported ERR-agonist effects on cardiac fatty-acid metabolism in heart failure models and on mitochondrial dysfunction in the aging kidney.
Two things must be stated directly. First, there is no human data of any kind — no trial, no phase I, no published human pharmacokinetics or toxicology. Second, the developers reported in a 2026 paper that SLU-PP-332 'lacks oral bioavailability,' the explicit motivation for developing the chemically distinct, orally active analog SLU-PP-915; all the mouse efficacy data was generated with intraperitoneal dosing.
The compound has also drawn attention from anti-doping laboratories, which have published metabolite characterizations for detection purposes.
The app deliberately shows no recommended dose ladder for this compound because no human protocol exists. The catalog carries an oral, once-daily entry with a 5-20 mg range extrapolated from rodent studies only — 5 mg as a conservative start, 10 mg as the commonly research-cited figure, 20 mg at the rodent-derived high end. Two caveats matter more than the numbers: the published mouse work used intraperitoneal injection, not oral dosing, and the developing laboratory states in a 2026 paper that SLU-PP-332 'lacks oral bioavailability,' which is why they built a separate orally active analog. An oral human dose is therefore an extrapolation from a route the compound was never shown to work by.
- Half-life
- Not characterized in humans; no published human pharmacokinetics
- Peak
- No human data
- Bioavailability
- Oral: negligible per the developers' own characterization. No human data.
Unknown in humans. In mice the transcriptional response is acute — exercise-associated genes are induced shortly after dosing — while body-composition and insulin-sensitivity changes accumulated over weeks of repeated administration.
Nothing, on any evidence basis. It should specifically not be combined with other compounds active at estrogen or estrogen-related receptors, since off-target and additive effects are entirely uncharacterized.
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
- PubChem - SLU-PP-332 Compound Summary, CID 5338394
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.